Online citations, reference lists, and bibliographies.
Please confirm you are human
(Sign Up for free to never see this)
← Back to Search

Reducing The Incidence And Severity Of Post Ercp Pancreatitis

W. Murray
Published 2005 · Medicine

Save to my Library
Download PDF
Analyze on Scholarcy
Share
Acute pancreatitis remains the commonest complication of ERCP (endoscopic retrograde cholangiopancreatography) with published incidence rates that have changed little over 30 years despite significant advances in endoscope and ERCP accessory technology and the introduction of structured ERCP training. Technique related risk factors for post ERCP pancreatitis have been recognised for many years and have been recently refined via large prospective audits. These studies have also revealed the importance of patient related factors and highlighted the high incidence of post ERCP pancreatitis in women being investigated for acalculus biliary pain or idiopathic recurrent acute pancreatitis. Sphincter of Oddi hypertension is often found to be present in this group of patients. Methods of preventing post ERCP pancreatitis have been sought for many years and numerous drugs have been tried using a variety of regimes with heterogeneous groups of patients. At present pancreatic duct stenting looks to be the most efficacious prophylactic method but is not for the beginner endoscopist. It is possible, however, by using a simple strategy to minimise the incidence of post ERCP pancreatitis and modulate its severity.
This paper references
10.1016/S0016-5107(91)70740-2
Endoscopic sphincterotomy complications and their management: an attempt at consensus.
P. Cotton (1991)
10.1067/MGE.2001.117550
Risk factors for post-ERCP pancreatitis: a prospective, multicenter study.
M. Freeman (2001)
10.1055/S-2007-1001390
Needle-knife papillotomy: a helpful and safe adjunct to endoscopic retrograde cholangiopancreatography in a selected population.
C. Rollhauser (1998)
10.3109/00365519709084587
Inhibition of serum phospholipase-A2 in acute pancreatitis by pharmacological agents in vitro.
A. Mäkelä (1997)
10.1111/j.1572-0241.1999.01072.x
Serum amylase measured four hours after endoscopic sphincterotomy is a reliable predictor of postprocedure pancreatitis
P. Testoni (1999)
10.1016/S0016-5107(98)70121-X
Major early complications from diagnostic and therapeutic ERCP: a prospective multicenter study.
S. Loperfido (1998)
10.1016/S0016-5107(02)70184-3
Safety and outcome of endoscopic snare excision of the major duodenal papilla.
I. Norton (2002)
Efficacy of Interleukin 10 ( IL 10 ) in the prevention of post - ERCP pancreatitis : a meta - analysis ( Abstract )
P Singh (2002)
10.1055/S-2002-23629
Sphincter of Oddi dysfunction: pancreaticobiliary sphincterotomy with pancreatic stent placement has a lower rate of pancreatitis than biliary sphincterotomy alone.
E. Fogel (2002)
Post-ERCP pancreatitis: patient and technique-related risk factors.
M. Freeman (2002)
10.1055/S-1999-13659
Severe and fatal complications after diagnostic and therapeutic ERCP: a prospective series of claims to insurance covering public hospitals.
R. Trap (1999)
10.1016/S0016-5107(02)70112-0
Risk factors for complications after performance of ERCP.
J. Vandervoort (2002)
10.1016/S0016-5107(97)70301-8
Transpapillary stenting of proximal biliary strictures: does biliary sphincterotomy reduce the risk of postprocedure pancreatitis?
P. Tarnasky (1997)
10.1016/S0002-9270(00)02387-X
Complications of diagnostic and therapeutic ERCP: a prospective multicenter study.
E. Masci (2001)
Common bile duct sphincter of Oddi stenting in patients with suspected sphincter dysfunction.
Goff Js (1995)
10.1067/MGE.2003.29
Transdermal glyceryl trinitrate for prevention of post-ERCP pancreatitis: A randomized double-blind trial.
M. Moretó (2003)
10.1016/S0016-5085(03)00384-6
Diclofenac reduces the incidence of acute pancreatitis after endoscopic retrograde cholangiopancreatography.
B. Murray (2003)
10.1016/S0016-5107(73)73873-6
Post-endoscopy pancreatitis and hyperamylasuria.
W. D. Blackwood (1973)
10.1097/00006676-198603000-00009
Hyperamylasaemia and Acute Pancreatitis Following Endoscopic Retrograde Cholangiopancreatography
G. Laferla (1986)
10.1046/J.0007-1323.2001.01842.X
Prospective randomized double‐blind placebo‐controlled trial of glyceryl trinitrate in endoscopic retrograde cholangiopancreatography‐induced pancreatitis
S. Sudhindran (2001)
10.1067/MGE.2003.61
A comparative study of postendoscopic sphincterotomy complications with various types of electrosurgical current in patients with choledocholithiasis.
G. Stefanidis (2003)
10.1111/j.1440-1746.2003.03297.x
Can somatostatin prevent post‐ERCP pancreatitis? Results of a randomized controlled trial
D. Arvanitidis (2004)
10.1136/GUT.35.1_SUPPL.S35
Effects of short chain fatty acids on gut morphology and function.
W. Scheppach (1994)
10.1016/S1091-255X(01)80059-7
Post-ERCP pancreatitis: Reduction by routine antibiotics
S. Räty (2001)
10.1016/S0016-5107(04)02013-9
Does prophylactic pancreatic stent placement reduce the risk of post-ERCP acute pancreatitis? A meta-analysis of controlled trials.
P. Singh (2004)
Can a 2 hour serum amylase estimation predict post ERCP acute pancreatitis ? ( Abstract )
CK MacKay (1994)
10.1016/S0016-5107(88)71332-2
Endoscopic Cannulation of the Ampulla of Vater: A Preliminary Report
W. S. Mccune (1968)
Common bile duct sphincter of Oddi stenting in patients with suspected sphincter dysfunction.
J. Goff (1995)
10.1056/NEJM199609263351301
Complications of endoscopic biliary sphincterotomy.
M. Freeman (1996)
10.1016/S0016-5085(98)70031-9
Pancreatic stenting prevents pancreatitis after biliary sphincterotomy in patients with sphincter of Oddi dysfunction.
P. Tarnasky (1998)
10.1016/S0016-5107(02)70431-8
Gabexate or somatostatin administration before ERCP in patients at high risk for post-ERCP pancreatitis: a multicenter, placebo-controlled, randomized clinical trial.
A. Andriulli (2002)
10.1016/S0016-5107(04)00353-0
Prevention of post-ERCP pancreatitis: a comprehensive review.
M. Freeman (2004)
Pharmacological prevention of post-ERCP pancreatitis: the facts and the fiction.
P. Testoni (2004)
10.1016/S0016-5107(92)70430-1
Pancreatitis following bile duct sphincter of Oddi manometry: utility of the aspirating catheter.
S. Sherman (1992)



This paper is referenced by
10.1136/flgastro-2017-100832
Does rectal diclofenac reduce post-ERCP pancreatitis? A district general hospital experience
G. Sheiybani (2017)
DICLOFENAC SÓDICO INTRAVENOSO EN LA PREVENCIÓN DE LA PANCREATITIS AGUDA POS COLANGIOPANCREATOGRAFIA RETROGRADA ENDOSCÓPICA, EN PACIENTES DEL HOSPITAL MILITAR CENTRAL DURANTE LOS AÑOS 2012-2013.
Hugo Mario Cardona Serna (2015)
10.1097/MOG.0B013E3280F9DF52
Liver and biliary tract disorders.
R. Moseley (2007)
10.7575/aiac.abcmed.15.03.02.07
Risk Factors of Pancreatitis after Endoscopic Retrograde Cholangiopancreatography
Shahryar Hashemzadeh (2015)
10.15360/1813-9779-2006-3-36-43
Reactive Pancreatitis Following Endoscopic Retrograde Cholangiopancreatography: Diagnosis, Prevention and Treatment
V. Moroz (2006)
Prevention of post-ERCP pancreatitis Post-ERCP pankreatitin önlenmesi
Ülkü SARITAfi ()
10.3904/kjim.2013.28.2.141
Can postendoscopic retrograde cholangiopancreatography pancreatitis be prevented by a pharmacological approach?
Y. K. Cheon (2013)
10.3904/kjim.2020.069
Prevention of post-endoscopic retrograde cholangiopancreatography pancreatitis with rectal non-steroidal anti-inflammatory drugs
Tae Kwon Park (2020)
10.1111/jgh.15303
Prevention of Post-Endoscopic Retrograde Cholangiopancreatography Pancreatitis with a Combination of Pharmacological Agents Based on Rectal Non-Steroidal Anti-Inflammatory Drugs: A Systematic Review and Network Meta-Analysis.
Hyoung-Chul Oh (2020)
10.3109/00365521003615647
Botulinum toxin may predict the outcome of endoscopic sphincterotomy in episodic functional post-cholecystectomy biliary pain
W. Murray (2010)
10.5772/26137
Endoscopic Retrograde Cholangiopancreatography (ERCP) Related Acute Pancreatitis
Z. Döbrönte (2012)
10.1097/01.mog.0000218954.17570.06
Liver and biliary tract disorders.
R. Moseley (2006)
10.1007/s10620-011-1695-x
Prophylactic Pancreatic Stents: Does Size Matter? A Comparison of 4-Fr and 5-Fr Stents in Reference to Post-ERCP Pancreatitis and Migration Rate
Albert Pahk (2011)
10.4318/TJG.2011.0302
Prevention of post-ERCP pancreatitis.
Ü. Sarıtaş (2011)
10.1007/s11605-017-3412-3
Diclofenac Does Not Reduce the Risk of Post-endoscopic Retrograde Cholangiopancreatography Pancreatitis in Low-Risk Units
Mia Rainio (2017)
10.3748/WJG.V13.I19.2655
Pancreatitis after endoscopic retrograde cholangio-pancreatography.
Ayman M Abdel Aziz (2007)
10.6092/1590-8577/2258
The role of nonsteroidal anti-inflammatory drugs in the prevention of post endoscopic retrograde cholangiopancreatography pancreatitis.
I. Sheikh (2014)
10.5580/329
ERCP in a district general hospital in England:a review of 1550 procedures over nine years
J. Penston (2008)
10.1016/j.ajg.2015.02.004
ERCP in a cohort of 759 cases: A 6-year experience of a single tertiary centre in Libya.
Ali Tumi (2015)
10.1007/978-1-4939-2501-8_13
Botulinum Toxin Therapy for Prevention of Postsurgical Pain
B. Jabbari (2015)
Semantic Scholar Logo Some data provided by SemanticScholar